Therapeutic advances in endocrinology and metabolismOct 10, 2025

GLP-1 receptor drugs may affect metabolism and reproduction in polycystic ovary syndrome, based on human and animal studies

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jun 27, 2026

Abstract

Essence

may affect both metabolic and reproductive features of .

Evidence

This review summarizes human and animal trial data on GLP-1RAs in PCOS, covering weight loss, insulin resistance, cardiovascular health, hypothalamic-gonadal signaling, menstrual irregularity, ovulation, ovarian morphology, inflammation, fertility, and drug combinations such as metformin.

Caveat

As a review rather than a new trial, it synthesizes heterogeneous evidence and cannot by itself establish which GLP-1RA regimens improve reproductive outcomes in PCOS.

Simplified

(PCOS) is a prevalent disorder in the modern world, affecting around 6%-20% of females of childbearing age. Hormonal and metabolic symptoms vary over time but often arise throughout puberty. Treatment includes lifestyle interventions as a first line of treatment. In certain cases, specific medications may be considered. However, there is a growing interest in using Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in PCOS due to their efficacy in weight loss, insulin resistance, and heart health. Aside from the metabolic role of GLP-1RAs, which aids in the relief of PCOS symptoms, there is also the possibility of direct involvement in reproductive health in PCOS, including its role in the hypothalamic-gonadal axis, menstrual irregularity, ovulation, ovarian morphology, anti-inflammatory properties, and fertility. This review discusses the latest data on GLP-1RAs' metabolic and reproductive health benefits in PCOS. Moreover, this article covers pharmaceutical interactions and synergistic effects of drugs, including metformin and other medications, with GLP-1RAs. It also conveys an overview of recent clinical trials utilizing GLP-1RAs to treat PCOS.

Key numbers

4.29 kg

Weight Reduction with

Weight loss after 12 weeks of treatment with exenatide.

86%

Improvement in Ovulation Rates

Ovulation rate in women treated with exenatide combined with metformin.

0.9%

Insulin Sensitivity Improvement

Reduction in HbA1c levels after treatment with .

Full Text

We can’t show the full text here under this license.

View Full Text ↗

Funding

Competing interests

0%of authors

0 of 7

authors report competing interests

7 report none

PubMed

GLP-1 receptor drugs may affect metabolism and reproduction in polycystic ovary syndrome, based on human and animal studies

Abstract

Key numbers

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief

Abstract

Key numbers

Full Text

Funding

Competing interests

Related papers

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief